Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD
Advertisement
Articles by Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD
Advertisement
Latest Updated Articles
JNJ-4496 Prevents Antigen Escape, May Work as Salvage Therapy in R/R LBCLPublished: June 25th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pembrolizumab/Enfortumab Vedotin in Muscle Invasive Bladder Cancer
2
Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer
3
How ADCs and BiTEs Are Propelling Change in Lung Cancer
4
Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors
5
